MARKET

OTLK

OTLK

Outlook Therapeutics Inc
NASDAQ
0.6766
+0.0276
+4.25%
Opening 12:13 09/04 EDT
OPEN
0.6599
PREV CLOSE
0.6490
HIGH
0.6962
LOW
0.6451
VOLUME
3.50M
TURNOVER
--
52 WEEK HIGH
2.538
52 WEEK LOW
0.1611
MARKET CAP
164.72M
P/E (TTM)
-0.7798
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at OTLK last week (0824-0828)?
Weekly Report · 4d ago
Why Now On-Demand Conference Spotlights Nine Emerging Biotech And Healthcare Stories
NASDAQ · 6d ago
Outlook Therapeutics Appoints Kevin Lundquist As CFO Ahead Of U.S. LYTENAVA Launch; Stock Up
NASDAQ · 08/28 06:05
Outlook Therapeutics Announces CFO Transition and Board Change
TipRanks · 08/27 20:29
Outlook CFO Lawrence Kenyon to step down, Kevin Lundquist to succeed
TipRanks · 08/27 20:15
Press Release: Outlook Therapeutics Appoints -2-
Dow Jones · 08/27 20:05
Press Release: Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA(TM)
Dow Jones · 08/27 20:05
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
Barchart · 08/27 08:01
More
About OTLK
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.

Webull offers Outlook Therapeutics Inc stock information, including NASDAQ: OTLK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTLK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OTLK stock methods without spending real money on the virtual paper trading platform.